REDUCE POSITION SIZE MODERATELY (15-20% trim), not the aggressive 25-40% trim; maintain remaining exposure with wider stop at $410

• ISRG printed all-time high quarterly revenue of $2.89 billion with 18.5% growth, EBITDA margin expanding to 41.6%, $1.06 billion operating cash flow last quarter, debt-free with $5.22 billion cash
• Valuation: 42x trailing P/E, 1.82 PEG ratio, 25% FCF margin expansion; argues premium multiple is anchored to actual delivery not speculative growth
• ISRG historically trades 35-60x forward earnings over multi-year cycles; floor only compresses to 22-25x in genuine growth scares with evidence of procedure volume rolling over
• Technical signals contradicting breakdown: volume declining into the decline, ATR compressed ~31% from mid-July, RSI forming bullish divergence against price, MACD histogram narrowing
• Current price $367; 50 SMA at $384.80; ATR at $11.79; prior bounce high at $401.27
• Opposes $395 stop as it sits only ~$10 above 50 SMA and below the $401.27 failed resistance—high probability of being hit by fake-out; recommends $410 stop above structural resistance cluster
• $377-384 is overhead resistance that failed twice recently—poor zone to sell into strength
• GLP-1 impact concentrated in bariatric procedures only; general surgery, urology, gynecology, thoracic, and head-and-neck largely unaffected; hospital capex, da Vinci 5 software velocity, and consumables economics intact
• Base case: 15-20% revenue growth, margin expansion, $2.5B+ FCF, gradual multiple normalization to 30-35x over 12-18 months—no miracles required
• Better entry triggers: confirmed break and close below $354 with elevated volume, or successful retest of 50 SMA at $384.80 on rising volume

→ vs aggressive: The 34% YTD drawdown is a belief about bearish pricing, not a fact—markets overshoot on the downside and fundamentals remain strong with all-time high revenue and margin expansion

→ vs aggressive: The 22-25x multiple compression scenario is presented as inevitable but is sloppy math—the floor only hits that level with genuine growth scares and evidence of procedure volume rolling over, which does not exist currently

→ vs aggressive: The $395 stop is the weakest part of the plan: it is essentially at the level that already failed twice as resistance, creating high-probability fake-out risk; tight stops in noisy regimes lead to repeated small losses that compound

→ vs aggressive: Selling into bounces near $377-384 is selling into supply zones where sellers have repeatedly overwhelmed buyers—not true 'selling into strength'

→ vs aggressive: The asymmetry argument (bull case needs three miracles, bear case needs one) builds a strawman—the actual base case requires no miracles: 15-20% growth, margin expansion, $2.5B+ FCF, gradual multiple normalization

→ vs aggressive: GLP-1 narrative is overstated—concentrated in bariatric procedures, not franchise-wide impairment; hospital capital commitments and recurring consumables economics remain intact

→ vs aggressive: The aggressive trim risks converting a paper loss on a quality compounder into a realized loss at a relative bottom—action bias masquerading as disciplined risk management

Trim 20-25% of position in phased manner ($367-$375 zone), set stop at $402-$405, hold remaining size with defined re-entry triggers

• Aggressive analyst's 22-25x multiple compression floor is recession-style, inappropriate for company with all-time-high quarterly revenue and 18.5% growth
• Multiple compressing in line with rates is re-rating within healthy range, not derating into impairment - 30-35x forward still means meaningful upside
• Technical setup shows momentum exhaustion: RSI higher lows, MACD histogram narrowing, ATR compressing 31% from mid-July, declining volume
• Death crosses have historically failed in ISRG when underlying business was intact (2018, 2022)
• Conservative analyst conflates 'good company' with 'good stock at this entry point' - pristine fundamentals and structural downtrend can coexist
• The 34% YTD drawdown is not irrelevant - evidence of market repricing that may not be complete
• $410 stop gives nearly 12% room (~10 ATRs of slack) - pseudo-stop that lets position do whatever it wants
• 15% trim crystallizes losses while providing minimal risk reduction - worst of both worlds
• Macro backdrop is being underweighted: 88% probability of no Fed cuts in 2026, 30% real chance of September hike
• Aggressive $395 stop is fake-out trap inside failed resistance cluster - will get stopped on routine 50 SMA retest
• Balanced stop at $402-$405 sits above $401.27 prior bounce high and below $409.02 upper Bollinger Band
• Catalysts are binary: Jackson Hole (this week), September 16 FOMC, Q3 procedure volume data
• Phased execution: sell 1/3 at current levels, 1/3 toward $375, final 1/3 at $384 if retest occurs
• Re-entry triggers: close below $354 with elevated volume, or sustained close above $384.80 on rising volume

→ vs aggressive: Multiple compression thesis has structural flaw - 22-25x is recession-style floor for company with all-time-high revenue and 18.5% growth, not natural resting place

→ vs aggressive: Asymmetry argument incomplete - bull case only needs Fed to stop being hawkish (6-12 month lag historically), not 'three miracles'

→ vs aggressive: Cannot dismiss bullish RSI divergence cleanly - combination of RSI higher lows, MACD histogram narrowing, ATR compressing 31%, declining volume is momentum exhaustion signature, not random noise

→ vs aggressive: Death crosses have failed multiple times in ISRG history when underlying business was intact (2018, 2022)

→ vs conservative: Framing all selling as 'selling low' ignores that 34% YTD drawdown is evidence of market repricing that may not be complete

→ vs conservative: $410 stop is nearly 12% wide with ~10 ATRs of slack - pseudo-stop that is functionally meaningless as risk control

→ vs conservative: 15% trim crystallizes realized loss while providing minimal risk reduction - worst of both worlds

→ vs conservative: Underweighting macro backdrop - 88% probability of no Fed cuts in 2026 and real 30% chance of September hike is not benign for 42x trailing earnings name

→ vs conservative: Cannot hold full size through Jackson Hole and Q3 data and claim to be managing risk - that is holding and hoping